2020 FILO建议:慢性淋巴细胞白血病的诊断和治疗

2020-09-23 Hemasphere . 2020 Sep 23;4(5):e473.

2020年9月,法国创新性白血病组织(FILO)慢性淋巴细胞白血病研究组发布了慢性淋巴细胞白血病的诊断和治疗建议。由于近期的重大进展,慢性淋巴细胞白血病(CLL)的管理正在发生变化,在不就的将来,新的

中文标题:

2020 FILO建议:慢性淋巴细胞白血病的诊断和治疗

英文标题:

Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)

发布机构:

发布日期:

2020-09-23

简要介绍:

2020年9月,法国创新性白血病组织(FILO)慢性淋巴细胞白血病研究组发布了慢性淋巴细胞白血病的诊断和治疗建议。由于近期的重大进展,慢性淋巴细胞白血病(CLL)的管理正在发生变化,在不就的将来,新的治疗方法将陆续出现。本文主要针对慢性淋巴细胞白血病的管理提供临床实践建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020 FILO建议:慢性淋巴细胞白血病的诊断和治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=74aef1c0020055c9, title=2020 FILO建议:慢性淋巴细胞白血病的诊断和治疗, enTitle=Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO), guiderFrom=Hemasphere . 2020 Sep 23;4(5):e473., authorId=0, author=, summary=2020年9月,法国创新性白血病组织(FILO)慢性淋巴细胞白血病研究组发布了慢性淋巴细胞白血病的诊断和治疗建议。由于近期的重大进展,慢性淋巴细胞白血病(CLL)的管理正在发生变化,在不就的将来,新的, cover=https://img.medsci.cn/20201031/1604156099639_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Wed Sep 23 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年9月,法国创新性白血病组织(FILO)慢性淋巴细胞白血病研究组发布了慢性淋巴细胞白血病的诊断和治疗建议。由于近期的重大进展,慢性淋巴细胞白血病(CLL)的管理正在发生变化,在不就的将来,新的治疗方法将陆续出现。本文主要针对慢性淋巴细胞白血病的管理提供临床实践建议。</p> </div> </div> </div>, tagList=[TagDto(tagId=4180, tagName=慢性淋巴细胞白血病)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=4180, guiderKeyword=慢性淋巴细胞白血病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3059, appHits=271, showAppHits=0, pcHits=652, showPcHits=2788, likes=1, shares=7, comments=21, approvalStatus=1, publishedTime=Sat Oct 31 23:09:01 CST 2020, publishedTimeString=2020-09-23, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat Oct 31 22:55:05 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 15:33:26 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 FILO建议:慢性淋巴细胞白血病的诊断和治疗.pdf)])
2020 FILO建议:慢性淋巴细胞白血病的诊断和治疗.pdf
下载请点击:
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1199641, encodeId=28ec11996414b, content=继续努力学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e845489837, createdName=金朝岁月, createdTime=Sat Mar 05 13:51:24 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007736, encodeId=cd66100e736dc, content=ddddd, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5185543565, createdName=ms4000000408264698, createdTime=Fri Aug 13 22:35:31 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001908, encodeId=619d1001908b2, content=ganxiefengxiang, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5185543565, createdName=ms4000000408264698, createdTime=Fri Jul 23 08:58:11 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970581, encodeId=ca5b9e0581cd, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/b2c0b965f17441e0a3e3d3183c10efd2/ba96cdef43d448e0942789db93c3d589.jpg, createdBy=e9c15503371, createdName=ms8000000167327353, createdTime=Thu Jun 03 14:20:28 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970580, encodeId=8e409e0580d3, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/b2c0b965f17441e0a3e3d3183c10efd2/ba96cdef43d448e0942789db93c3d589.jpg, createdBy=e9c15503371, createdName=ms8000000167327353, createdTime=Thu Jun 03 14:20:22 CST 2021, time=2021-06-03, status=1, ipAttribution=)]
    2022-03-05 金朝岁月

    继续努力学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1199641, encodeId=28ec11996414b, content=继续努力学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e845489837, createdName=金朝岁月, createdTime=Sat Mar 05 13:51:24 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007736, encodeId=cd66100e736dc, content=ddddd, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5185543565, createdName=ms4000000408264698, createdTime=Fri Aug 13 22:35:31 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001908, encodeId=619d1001908b2, content=ganxiefengxiang, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5185543565, createdName=ms4000000408264698, createdTime=Fri Jul 23 08:58:11 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970581, encodeId=ca5b9e0581cd, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/b2c0b965f17441e0a3e3d3183c10efd2/ba96cdef43d448e0942789db93c3d589.jpg, createdBy=e9c15503371, createdName=ms8000000167327353, createdTime=Thu Jun 03 14:20:28 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970580, encodeId=8e409e0580d3, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/b2c0b965f17441e0a3e3d3183c10efd2/ba96cdef43d448e0942789db93c3d589.jpg, createdBy=e9c15503371, createdName=ms8000000167327353, createdTime=Thu Jun 03 14:20:22 CST 2021, time=2021-06-03, status=1, ipAttribution=)]
    2021-08-13 ms4000000408264698

    ddddd

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1199641, encodeId=28ec11996414b, content=继续努力学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e845489837, createdName=金朝岁月, createdTime=Sat Mar 05 13:51:24 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007736, encodeId=cd66100e736dc, content=ddddd, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5185543565, createdName=ms4000000408264698, createdTime=Fri Aug 13 22:35:31 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001908, encodeId=619d1001908b2, content=ganxiefengxiang, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5185543565, createdName=ms4000000408264698, createdTime=Fri Jul 23 08:58:11 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970581, encodeId=ca5b9e0581cd, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/b2c0b965f17441e0a3e3d3183c10efd2/ba96cdef43d448e0942789db93c3d589.jpg, createdBy=e9c15503371, createdName=ms8000000167327353, createdTime=Thu Jun 03 14:20:28 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970580, encodeId=8e409e0580d3, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/b2c0b965f17441e0a3e3d3183c10efd2/ba96cdef43d448e0942789db93c3d589.jpg, createdBy=e9c15503371, createdName=ms8000000167327353, createdTime=Thu Jun 03 14:20:22 CST 2021, time=2021-06-03, status=1, ipAttribution=)]
    2021-07-23 ms4000000408264698

    ganxiefengxiang

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1199641, encodeId=28ec11996414b, content=继续努力学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e845489837, createdName=金朝岁月, createdTime=Sat Mar 05 13:51:24 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007736, encodeId=cd66100e736dc, content=ddddd, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5185543565, createdName=ms4000000408264698, createdTime=Fri Aug 13 22:35:31 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001908, encodeId=619d1001908b2, content=ganxiefengxiang, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5185543565, createdName=ms4000000408264698, createdTime=Fri Jul 23 08:58:11 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970581, encodeId=ca5b9e0581cd, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/b2c0b965f17441e0a3e3d3183c10efd2/ba96cdef43d448e0942789db93c3d589.jpg, createdBy=e9c15503371, createdName=ms8000000167327353, createdTime=Thu Jun 03 14:20:28 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970580, encodeId=8e409e0580d3, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/b2c0b965f17441e0a3e3d3183c10efd2/ba96cdef43d448e0942789db93c3d589.jpg, createdBy=e9c15503371, createdName=ms8000000167327353, createdTime=Thu Jun 03 14:20:22 CST 2021, time=2021-06-03, status=1, ipAttribution=)]
    2021-06-03 ms8000000167327353

    感谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1199641, encodeId=28ec11996414b, content=继续努力学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e845489837, createdName=金朝岁月, createdTime=Sat Mar 05 13:51:24 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007736, encodeId=cd66100e736dc, content=ddddd, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5185543565, createdName=ms4000000408264698, createdTime=Fri Aug 13 22:35:31 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001908, encodeId=619d1001908b2, content=ganxiefengxiang, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5185543565, createdName=ms4000000408264698, createdTime=Fri Jul 23 08:58:11 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970581, encodeId=ca5b9e0581cd, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/b2c0b965f17441e0a3e3d3183c10efd2/ba96cdef43d448e0942789db93c3d589.jpg, createdBy=e9c15503371, createdName=ms8000000167327353, createdTime=Thu Jun 03 14:20:28 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970580, encodeId=8e409e0580d3, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/b2c0b965f17441e0a3e3d3183c10efd2/ba96cdef43d448e0942789db93c3d589.jpg, createdBy=e9c15503371, createdName=ms8000000167327353, createdTime=Thu Jun 03 14:20:22 CST 2021, time=2021-06-03, status=1, ipAttribution=)]
    2021-06-03 ms8000000167327353

    谢谢

    0